Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Individuellt Anpassad, Övervakad, Distansbaserad Träningsintervention för att Förbättra Fysisk Funktion hos Överlevare av Gastroesofagealcancer i Stadium I-III, PRECISE-studien (PRECISE)

3 november 2026 uppdaterad av: Jonsson Comprehensive Cancer Center

En pilotstudie av en individuellt anpassad, övervakad, fjärrlevererad träningsintervention för att förbättra den fysiska funktionen hos överlevare av gastroesofageal cancer (PRECISE-studien)

This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors. Modern treatments for gastroesophageal cancer are effective at treating the cancer but are often aggressive, can be difficult for patients to tolerate, and can lead to significant debilitation and a loss of independence. Exercise is one promising intervention that could improve physical function in patients with gastroesophageal cancer after finishing systemic treatment. Home based exercise interventions in patients with cancer during and after chemotherapy can improve fatigue and function. An individually tailored, supervised, remote exercise intervention may improve physical function for stage I-III gastroesophageal cancer survivors.

Studieöversikt

Detaljerad beskrivning

PRIMARY OBJECTIVE:

I. To determine the feasibility of the exercise intervention, as measured by the percentage of participants who attend at least 80% of the exercise sessions and complete the post-intervention functional assessment.

SECONDARY OBJECTIVES:

I. To determine other measures of feasibility of the exercise intervention, including eligibility, recruitment, and achievement of exercise goals.

II. To determine the change in measures of physical function (Short Physical Performance Battery [SPPB], grip strength, Two Minute Step Test [TMST], Activities of Daily Living [ADL], and instrumental ADL) from baseline to end of study.

III. To determine the change in frailty status (Deficit Accumulation Index [DAI]) from baseline to end of study.

IV. To determine the change in measures of cognitive function (Montreal Cognitive Assessment [MOCA] and Patient Reported Outcomes Measurement Information System [PROMIS] Cognitive Function Short Form) from baseline to end of study.

V. To determine the change in anxiety (General Anxiety Disorder-7 [GAD-7]) from baseline to end of study.

VI. To determine the change in depression (Patient Health Questionnaire-8 [PHQ-8]) from baseline to end of study.

VII. To determine the change in sleep quality (Insomnia Severity Index) from baseline to end of study.

VIII. To determine the change in quality of life (Short Form [SF]-36) from baseline to end of study.

IX. To evaluate adverse events (Patient Reported Outcomes version of Common Terminology Criteria for Adverse Events [PRO-CTCAE] and Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0) during the study intervention.

X. To identify patient perspectives on the whether or not the study intervention was worthwhile.

EXPLORATORY OBJECTIVES:

I. To determine the reliability of using remote monitoring devices to measure functional health in real-time during the study intervention.

II. To determine the change in biomarkers of aging from baseline to end of study.

OUTLINE:

Patients receive access to the Moterum application and complete remotely delivered, supervised exercise sessions, over 1 hour, 3 times per week for 8 weeks. Sessions consist of both aerobic and resistance training exercises. Patients also receive written instructions and videos of strengthening exercises. Patients undergo blood sample collection throughout the study.

After completion of study intervention, patients are followed up at 6 months.

Studietyp

Interventionell

Inskrivning (Beräknad)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Los Angeles, California, Förenta staterna, 90095
        • Rekrytering
        • UCLA / Jonsson Comprehensive Cancer Center
        • Kontakt:
        • Huvudutredare:
          • Jingran Ji, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Adults ≥ 18 years old at the start of study treatment
  • Diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric cancer. Histology can be adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma
  • Treated with at least one systemic therapy (chemotherapy or immunotherapy) and within 12 months of completing curative intent gastroesophageal cancer (GEC) treatment
  • Have evidence of physical function impairment, defined as a SPPB score of < 12) at baseline
  • Ability to understand English and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients with stage I disease who underwent endoscopic resection or surgery alone without perioperative systemic therapy
  • Patients with stage IV disease or unresectable locally advanced disease taking a palliative treatment approach without a clearly defined end of treatment
  • Patients currently receiving ongoing systemic therapy for GEC or another malignancy
  • Patients who are unable to provide informed consent
  • Any other condition or pre-existing co-morbidity that would, in the Investigator's judgment, contraindicate the participation in the study due to safety concerns with study procedures
  • Currently participating in another exercise intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion/fatigue, or cognitive function

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Supportive care (Remote exercise intervention)

Patients receive access to the Moterum application and complete remotely delivered, supervised exercise sessions, over 1 hour, 3 times per week for 8 weeks. Sessions consist of both aerobic and resistance training exercises. Patients also receive written instructions and videos of strengthening exercises. Patients undergo blood sample collection throughout the study.

Undergo blood sample collection

Andra namn:
  • Biologisk provsamling
  • Bioprov insamlat
  • Provsamling

Ancillary studies

Ancillary studies

Ancillary studies

Receive written instructions

Andra namn:
  • Utbildning för intervention
  • Intervention by Education
  • Intervention genom utbildning
  • Intervention, utbildning

Receive videos of strengthening exercises

Andra namn:
  • Utbildning för intervention
  • Intervention by Education
  • Intervention genom utbildning
  • Intervention, utbildning

Compete exercise sessions

Receive access to Moterum application

Ancillary studies

Andra namn:
  • Fysisk konditionstestning
  • Fysisk funktionstestning

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of participants who attend at least 80% of the exercise sessions and complete the post-intervention functional assessment
Tidsram: At 8 weeks

Will use descriptive statistics to summarize the participant population, feasibility metrics, and safety data. The study will be deemed feasible if > 60% (12 or more) of the 20 enrolled participants are retained.

At 8 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Andel patienter som screenas som kvalificerar för interventionen
Tidsram: Upp till 16 månader
Upp till 16 månader
Andel berättigade patienter som samtycker till att delta i interventionen
Tidsram: Upp till 6 månader
Upp till 6 månader
Procentandel av berättigade deltagare som uppnår varaktighets- och intensitetsmålen för de aeroba och muskelstärkande övningarna vid studiens slut
Tidsram: Upp till 8 veckor
Upp till 8 veckor
Change in physical function
Tidsram: From baseline to 8 weeks

Assessed via Short Physical Performance Battery. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention.

From baseline to 8 weeks
Change in grip strength
Tidsram: From baseline to 8 weeks

Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention.

From baseline to 8 weeks
Change in physical function
Tidsram: From baseline to 8 weeks

Assessed via the two minute step test. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The two-minute step test is administered by measuring the midpoint of the participant's patella and the top of their iliac crest and measuring how many times the participant's right knee can reach this point while marching in place for 2 minutes. A higher step count means a better outcome.

From baseline to 8 weeks
Change in activities of daily living
Tidsram: From baseline to 8 weeks

Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The activities of daily living assessment is a calculated from the physical component score of the Short Form-36 health survey. This section consists of 10 items that assess different physical activity domains. Each item has a specific response scale which corresponds to a number. These numbers are summed and transformed into a 0-100 scale, where 0 indicates the worst health and 100 indicates the best health.

From baseline to 8 weeks
Change in instrumental activities of daily living
Tidsram: From baseline to 8 weeks

Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The instrumental activities of daily living assessment is a 10 items survey that assess different physical activity domains. Each item will be rated and scored based on responses denoting level of limitation (a lot, a little, not at all). The total score ranges from 0 to 100 and higher scores means a better outcome.

From baseline to 8 weeks
Change in frailty status
Tidsram: From baseline to 6 months

Assessed via Deficit Accumulation Index. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The Deficit Accumulation Index (DAI) is a 50-item frailty index that is derived from the Cancer and Aging Research Group geriatric assessment. The DAI evaluates deficits in multiple geriatric assessment domains. Scores range from 0-1 with a score of 0.0 representing no detected deficits and 1.0 representing the maximum deficit. Based on the score, participants will be categorized into three categories of health status: robust, prefrail, or frail.

From baseline to 6 months
Change in cognitive function
Tidsram: From baseline to 6 months

Assessed via Montreal Cognitive Assessment. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The Montreal Cognitive Assessment (MoCA) test is a series of questions and assessments to measure eight domains of cognitive function. The MoCA is score from 0-30 with lower scores indicating worse cognitive impairment. A score of <25 suggests some degree of cognitive impairment.

From baseline to 6 months
Change in cognitive function
Tidsram: From baseline to 6 months

Assessed via Patient Reported Outcomes Measurement Information System Cognitive Function Short Form. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The PROMIS Short Form v2.0 - Cognitive Function Short Form 8a provides a self-reported measure of cognitive function consisting of 8 items. Each item includes a statement related to cognitive function that the patient would rate with an attribution (very often (several times a day), often (about once a day), sometimes (two or three times), rarely (once), never) that ranges from 0-5. The items will be summed to obtain a composite score from 0-40 and higher scores indicate better cognitive function.

From baseline to 6 months
Change in quality of life
Tidsram: From baseline to 6 months

Assessed via 36-Item Short Form Survey. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The 36-Item Short Form Health Survey (SF-36) is a composite measure of quality of life that includes 36 items related to physical (10 items) and social functioning (2 items), pain (2 items), role limitations due to physical health (4 items) and emotional problems (3 items), energy/fatigue (4 items), emotional well-being (5 items), and health perceptions (6 items). Each item is scored on a 0 to 100 range, in which a high score represents a more favorable health state.

From baseline to 6 months
Change in sleep quality
Tidsram: From baseline to 6 months

Assessed via Insomnia Severity Index. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The Insomnia Severity Index is a self-rated questionnaire that assesses sleep problems over a 2-week time interval. Higher scores indicate more acute symptoms of insomnia (no clinically significant insomnia [0-7], subthreshold insomnia [8-14], moderate clinical insomnia [15-21], severe clinical insomnia [22-28]).

From baseline to 6 months
Change in anxiety
Tidsram: From baseline to 6 months

Assessed via General Anxiety Disorder-7. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The General Anxiety Disorder-7 is a 7-item questionnaire that assesses anxiety severity over a 2-week time interval. This is calculated by assigning scores of 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day) to each response. GAD-7 total score for the 7 items ranges from 0 to 21 with higher scores indicating more anxiety (minimal anxiety [0-4], mild anxiety [5-9], moderate anxiety [10-14], severe anxiety [15-21]).

From baseline to 6 months
Change in depression
Tidsram: From baseline to 6 months

Assessed via Patient Health Questionnaire-8. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. The Patient Health Questionnaire-8 is an 8-item questionnaire that assesses depression over a 2-week time interval. This is calculated by assigning scores of 0 (not at all), 1 (several days), 2 (more than half the days), and 3 (nearly every day) to each response. Higher scores indicate a higher likelihood of clinical depression.

From baseline to 6 months
Incidence of adverse events
Tidsram: Up to 8 weeks

Assessed via National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Will be determined at each time point per patient as the presence (yes/no) of toxicities of grade ≥ 2. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. Adverse Events (AEs) experienced will be captured as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0). After grading, each AE will be assigned an attribution by the treating clinician (unlikely, possibly, probably, or definitely related to study agent).

Up to 8 weeks
Incidence of patient reported adverse events
Tidsram: Up to 8 weeks

Assessed via Patient Reported Outcomes version of CTCAE. Will perform exploratory statistical comparisons between baseline and end of study endpoints using t-tests and Fisher exact tests to explore the efficacy of the exercise intervention. Patient-reported Adverse Events (PRO-CTCAE) is a patient-reported outcome measurement system developed to evaluate symptomatic toxicity in patients on cancer clinical trials. Each item is scored 0-4 with higher scores indicated more severe symptoms. No total score is calculated.

Up to 8 weeks
Patient perspectives on whether or not the study intervention was worthwhile
Tidsram: At 8 weeks

Assessed via Was it Worth It (WIWI) questionnaire. Will use descriptive statistics to summarize the proportion of participants who answer 'yes,' 'uncertain,' and 'no' to the items in the WIWI Questionnaire and compare responses between participants with improvement in physical function and those without, bivariately and multivariately controlling for other factors.

At 8 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jingran Ji, MD, UCLA / Jonsson Comprehensive Cancer Center

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

11 september 2026

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 september 2028

Studieregistreringsdatum

Först inskickad

10 februari 2026

Först inskickad som uppfyllde QC-kriterierna

23 februari 2026

Första postat (Faktisk)

27 februari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera